Dr Pete Jackson

Dr Jackson is an experienced UK-based serial entrepreneur in the life sciences sector. Over the past 18 years, he has created seven new companies, developing novel therapeutics across infection, oncology and immunology, as well as in agrochemicals and life sciences services. Dr Jackson has over 30 years’ experience in the sector, previously holding senior executive roles including Vice President of Avecia’s Pharmaceutical Products business unit, following senior commercial and R&D positions at predecessor companies Zeneca and ICI.

In 2015, Dr Jackson chaired the steering committee created to establish the UK’s translational R&D centre focused on antimicrobial resistance, the AMR Centre, which in 2020 was renamed Infex Therapeutics, where he now serves as the CEO. Dr Jackson was a member of the Project Advisory Group for NICE/NHS England’s antibiotic reimbursement trial, and also serves as a Senior Advisor on AMR to the Milken Institute in Washington DC. Dr Jackson is a graduate in physical chemistry from the University of East Anglia, and holds a doctorate in magnetic resonance from the University of Durham.